Early stage of antibody-mediated rejection after lung transplantation： A case report and literature review.
10.11817/j.issn.1672-7347.2021.210515
- Author:
Zhenkun XIA
1
;
Mingjiu CHEN
2
;
Bei QING
2
;
Wei WANG
2
;
Linguo GU
2
;
Yunchang YUAN
3
Author Information
1. Department of Thoracic Surgery, Second Xiangya Hospital, Central South University, Changsha 410011, China. xwvfye@csu.edu.cn.
2. Department of Thoracic Surgery, Second Xiangya Hospital, Central South University, Changsha 410011, China.
3. Department of Thoracic Surgery, Second Xiangya Hospital, Central South University, Changsha 410011, China. yuanyc@csu.edu.cn.
- Publication Type:Review
- Keywords:
antibody-mediated rejection;
lung transplantation;
treatment
- MeSH:
Graft Rejection;
Graft Survival;
HLA Antigens;
Humans;
Isoantibodies;
Lung Transplantation/adverse effects*;
Male
- From:
Journal of Central South University(Medical Sciences)
2021;46(10):1172-1176
- CountryChina
- Language:English
-
Abstract:
Antibody-mediated rejection (AMR) is a rare and serious complication after lung transplantation, with no characteristic of pathological manifestation, no systematic standard treatment, and the poor efficacy and prognosis. We reported a case of early AMR after lung transplantation and the relevant literature has been reviewed. A male patient presented with symptoms of cold 99 days after transplantation and resolved after symptomatic treatment. He admitted to the hospital 14 days later because of a sudden dyspnea and fever. Anti-bacteria, anti-fungi, anti-virus, and anti-pneumocystis carinii treatment were ineffective, and a dose of 1 000 mg methylprednisolone did not work too. The patient's condition deteriorated rapidly and tracheal intubation was done to maintain breathing. Serum panel reactive antibody and donor specific antibody showed postive in humen leukocyte antigen (HLA) II antibody. Pathological examination after transbronchial transplantation lung biopsy showed acute rejection. Clinical AMR was diagnosed combined the donor-specific antibody with the pathological result. The patient was functionally recovered after combined treatment with thymoglobuline, rituximab, plasmapheresis, and immunoglobulin. No chronic lung allograft dysfunction was found after 3 years follow up. We should alert the occurrence of AMR in lung transplantation recipient who admitted to hospital with a sudden dyspnea and fever while showed no effect after common anti-infection and anti-rejection treatment. Transbronchial transplantation lung biopsy and the presence of serum donor-specific antibody are helpful to the diagnosis. The treatment should be preemptive and a comprehensive approach should be adopted.
